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Continuous manufacturing (CM) introduces the benefits of cost efficiency, reliability and scalability for the 
manufacturing of biopharmaceuticals. Higher flexibility, smaller facility footprints and cost of goods benefits are 
advantages of this production mode. It offers high flexibility in regard of demand changes from clinical to launch 
and for volatile market dynamics. In combination with disposable equipment, faster time-to-market and closed 
processing seems feasible. Bayer´s unique CM platform consists of a series of downstream processing (DSP) 
unit operations through which the drug substance moves continuously and all unit operations happen more or 
less in parallel at the same time. The technology offers the potential to make Quality by Design (QbD) a reality 
(with continuously monitored process parameters and real-time feedback process control to maintain quality-
indicating parameters within limits at all times, multi-variate data analysis). Individual unit operations are 
intelligently integrated and critical process parameters are monitored and controlled in real-time. Conditioning 
modules allow immediate corrective actions to be executed in an automated fashion to maintain the entire 
process in a state of control with low batch-to-batch variability. In addition, online sampling and testing functions 
provide early warning of potential excursions. By reduced manual interference this will also lead to reduction of 
operator errors and according deviations. Manufacturing facilities will be significantly less capital-intensive (e.g. 
by simpler layout) than large, traditional batch facilities as disposable technology and aseptic connections offer 
superior protection against bioburden ingress and other forms of contamination. The presentation also intends 
to illustrate comparability of CM versus batch processing in a side-by-side approach covering process 






Figure 1 – Bayer´s MoBiDiK technology platform for continuous downstream processing 
